Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019064468) ORALLY DISINTEGRATING TABLET
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/064468 International Application No.: PCT/JP2017/035381
Publication Date: 04.04.2019 International Filing Date: 29.09.2017
IPC:
A61K 31/423 (2006.01) ,A61K 9/20 (2006.01) ,A61K 47/32 (2006.01) ,A61K 47/38 (2006.01) ,A61P 25/16 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
41
having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
42
Oxazoles
423
condensed with carbocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9
Medicinal preparations characterised by special physical form
20
Pills, lozenges or tablets
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47
Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
30
Macromolecular compounds
32
Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47
Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
30
Macromolecular compounds
36
Polysaccharides; Derivatives thereof
38
Cellulose; Derivatives thereof
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25
Drugs for disorders of the nervous system
14
for treating abnormal movements, e.g. chorea, dyskinesia
16
Anti-Parkinson drugs
Applicants:
武田テバファーマ株式会社 TEVA TAKEDA PHARMA LTD. [JP/JP]; 愛知県名古屋市中村区太閤1-24ー11 24-11, Taiko 1-chome, Nakamura-ku, Nagoya-shi, Aichi 4530801, JP
Inventors:
洞口 陽彦 HORAGUCHI Haruhiko; JP
吉村 克弘 YOSHIMURA Katsuhiro; JP
Agent:
特許業務法人特許事務所サイクス SIKS & CO.; 東京都中央区京橋一丁目8番7号 京橋日殖ビル8階 8th Floor, Kyobashi-Nisshoku Bldg., 8-7, Kyobashi 1-chome, Chuo-ku, Tokyo 1040031, JP
Priority Data:
2017-18741728.09.2017JP
Title (EN) ORALLY DISINTEGRATING TABLET
(FR) COMPRIMÉS ORODISPERSIBLES
(JA) 口腔内崩壊錠
Abstract:
(EN) An orally disintegrating tablet which comprises zonisamide as an active ingredient and is free from crystalline cellulose or corn starch but contains crospovidone and low substituted hydroxypropylcellulose as pharmaceutical additives, wherein the content of crospovidone is 1-10 mass% inclusive relative to the total mass of the tablet. In the orally disintegrating tablet, a decrease in hygroscopicity and deterioration in dissolution properties following moisture absorption are avoided.
(FR) La présente invention concerne un comprimé orodispersible qui comprend du zonisamide en tant que principe actif et qui est exempt de cellulose cristalline ou d'amidon de maïs mais contient de la crospovidone et de l'hydroxypropylcellulose faiblement substituée en tant qu'additifs pharmaceutiques, la teneur en crospovidone étant de 1-10 % en masse inclus, par rapport à la masse totale du comprimé. Dans le comprimé orodispersible, une diminution de l'hygroscopicité et une détérioration des propriétés de dissolution après l'absorption d'humidité sont évitées.
(JA) ゾニサミドを有効成分として含み、製剤用添加物として結晶セルロース及びトウモロコシデンプンを含有せず、クロスポビドン及び低置換度ヒドロキシプロピルセルロースを含み、錠剤の全質量に対してクロスポビドンの量が1質量%以上、10質量%以下である、吸湿性及び吸湿後の溶出特性悪化を回避した口腔内崩壊錠。
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)